

# Johnson & Johnson

## Expanding Access to Our Medicines

As a leading global health care company, Johnson & Johnson has an important responsibility to do all it can to address unmet medical needs. This responsibility includes the need to make our medicines, vaccines, and diagnostics accessible to patients living in resource-limited settings. We are proud our commitment to global health is continuing to make a difference in enhancing access and contributing sustainably to advance healthcare for the long-term for the most vulnerable populations.

### Our Comprehensive Global Efforts to Improve Access to Medicine

The 2014 Access to Medicine Index documents significant progress during the last two years (June 2012 – May 2014) toward the goal of reaching the millions of people living in low- and middle-income countries in need of treatment and care. Our global efforts to benefit patients across the ATMI's seven areas of activity include:



#### General Access to Medicine Management Unifying Our Access Commitments

In January 2014, we launched Janssen Global Public Health, unifying our commitment to research, develop, and deliver medical innovations to address the world's greatest unmet public health needs.



#### Public Policy & Market Influence Engaging Local Stakeholders

Johnson & Johnson works closely with local partners to build strategies around specific regional medical needs. In Colombia and Brazil, for example, these relationships have supported new access initiatives for at-risk populations.



#### Research & Development Leading in "Child-Size" Medicine Development

With eight pediatric pipeline products, Johnson & Johnson is the industry leader in the development of treatments for children living in developing countries.



#### Pricing, Manufacturing & Distribution Piloting Equitable Pricing Strategies

We're piloting new financing models and strategies to improve the affordability of our medicines in emerging countries where many people continue to live in poverty.



#### Patents & Licensing Waiving Our Patent Rights

In November 2012, Johnson & Johnson announced it would not enforce patents for the HIV medicine darunavir in resource-limited settings for medically acceptable generic versions of this important medicine.



#### Capability Advancement Speeding Access to New Treatments

In April 2014, we began collaborating with the Stop TB Partnership's Global Drug Facility to enhance access to our new MDR-TB drug for eligible countries.



#### Drug Donations & Philanthropy Expanding Pediatric Donations

Johnson & Johnson has substantially broadened its drug donations to treat pediatric HIV in sub-Saharan Africa and intestinal worms in children across the developing world.

### Growing Our Commitment: 2014 Compared to 2012

Over the last 2 years, Johnson & Johnson has increased and broadened its dedication to discover, develop, and deliver lifesaving medicines to reach as many patients as possible.

#### ATMI 2012 included:



7 Medicines



4 Vaccines



1 Diagnostic



1 Donation Program

#### ATMI 2014 included:



16 Medicines



4 Vaccines



2 Diagnostics / 6 Contraceptives



4 Donation Programs

### Johnson & Johnson Key Performance Measures

The ATMI framework covers **seven areas of focus** that experts consider most relevant to access to medicine, across **four aspects of company action**: commitment, transparency, performance, and innovation.

